Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats

• Published in: Archives of pharmacal research Vol. 39; no. 4; pp. 539 - 546
• Main Authors: Kim, Dong Wuk, Kim, Young Hun, Yousaf, Abid Mehmood, Kim, Dong Shik, Kwon, Taek Kwan, Park, Jung Hee, Kim, Yong Il, Park, Jae-Hyun, Jin, Sung Giu, Kim, Kyung Soo, Cho, Kwan Hyung, Li, Dong Xun, Kim, Jong Oh, Yong, Chul Soon, Woo, Jong Soo, Choi, Han-Gon
• Format: Journal Article
• Language: English
• Published: Seoul Pharmaceutical Society of Korea 01.04.2016; 대한약학회
• Subjects: Acetates - administration & dosage; Acetates - chemistry; Acetates - pharmacokinetics; Acetates - standards; Administration, Oral; Animals; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - chemistry; Anti-Asthmatic Agents - pharmacokinetics; Anti-Asthmatic Agents - standards; Cellulose - chemistry; Drug Stability; Excipients - chemistry; Fumarates - chemistry; Glycerol - chemistry; Male; Medicine; Pharmacology/Toxicology; Pharmacy; Quinolines - administration & dosage; Quinolines - chemistry; Quinolines - pharmacokinetics; Quinolines - standards; Rats, Sprague-Dawley; Research Article; Solubility; Suspensions; Technology, Pharmaceutical - methods; Therapeutic Equivalency; 약학; Stability; Bioavailability; Oral suspension; Dissolution; Montelukast sodium
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-015-0664-x

To develop a montelukast sodium–loaded stable oral suspension bioequivalent to the commercial granules in rats, several montelukast sodium-loaded suspensions were prepared with a suspending agent, stabilizers and anti-aggregation agents, and their stabilities were investigated by visually observing the sedimentation phenomenon and determining the concentration of the degradation product. Moreover, dissolution and pharmacokinetic studies of the optimized formulation were examined in rats compared to commercial montelukast sodium-loaded granules. Avicel RC-591 (Avicel), a suspending agent, prevented the sedimentation of these suspensions at >2.496 (w/v) per cent composition. Amongst the stabilizers tested, fumaric acid provided the lowest concentration of montelukast sulphoxide (a degradation product) in these suspensions at 40 °C, demonstrating its excellent stabilizing activity. Furthermore, as an anti-aggregation agent, glycerin gave lower amounts of degradation product than those with poloxamer 407 and Tween 80. In particular, montelukast-loaded oral suspension, an aqueous suspension containing montelukast sodium/Avicel/fumaric acid/glycerin at a concentration of 312/2496/15.6/62.4 (mg/100 ml), and the commercial granules exhibited similar dissolution profiles in 0.5 % (w/v) aqueous solution of sodium lauryl sulphate. Moreover, the pharmacokinetics in rats provided by this suspension was comparable to that of the commercial granules, suggesting that they were bioequivalent. In addition, it was physically and chemically stable at 40 °C for at least 6 months. Thus, this montelukast sodium-loaded oral suspension, with bioequivalence to the commercial granules and excellent stability, could be a prospective dosage form for the treatment of asthma.